Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000542
First received: October 27, 1999
Last updated: February 4, 2009
Last verified: February 2009
  Purpose

To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.


Condition Intervention Phase
Cardiovascular Diseases
Coronary Disease
Diabetes Mellitus
Heart Diseases
Hypercholesterolemia
Hypertension
Myocardial Infarction
Myocardial Ischemia
Heart Failure
Drug: Inhibitors, ACE
Drug: amlodipine
Drug: lisinopril
Drug: doxazosin
Drug: chlorthalidone
Drug: pravastatin
Behavioral: diet, fat-restricted
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: August 1993
Study Completion Date: March 2002
Primary Completion Date: March 2002 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Men and women hypertensive patients, ages 55 and above. A total of 36 percent were diabetics.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000542

Sponsors and Collaborators
Investigators
Investigator: Barry Davis University of Texas
  More Information

Additional Information:
Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00000542     History of Changes
Other Study ID Numbers: 85
Study First Received: October 27, 1999
Last Updated: February 4, 2009
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Myocardial Ischemia
Coronary Artery Disease
Coronary Disease
Diabetes Mellitus
Heart Diseases
Heart Failure
Hypercholesterolemia
Hypertension
Infarction
Ischemia
Myocardial Infarction
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Pathologic Processes
Necrosis
Angiotensin-Converting Enzyme Inhibitors
Lisinopril
Antihypertensive Agents
Chlorthalidone
Amlodipine
Doxazosin
Pravastatin

ClinicalTrials.gov processed this record on August 28, 2014